JPMorgan Chase & Co. Lowers Illumina (NASDAQ:ILMN) Price Target to $120.00

Illumina (NASDAQ:ILMN) had its price target dropped by investment analysts at JPMorgan Chase & Co. from $130.00 to $120.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 0.23% from the company’s current price.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Illumina in a research note on Monday, December 29th. Stifel Nicolaus upped their price target on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. UBS Group reissued a “neutral” rating and issued a $135.00 price objective on shares of Illumina in a research report on Friday. Evercore ISI set a $150.00 price objective on shares of Illumina in a research note on Friday. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Six research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $130.00.

Illumina Stock Performance

ILMN opened at $119.72 on Friday. The company has a 50 day simple moving average of $138.43 and a two-hundred day simple moving average of $116.26. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm has a market cap of $18.29 billion, a P/E ratio of 21.97, a PEG ratio of 1.99 and a beta of 1.45. Illumina has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 32.33% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts forecast that Illumina will post 4.51 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares in the company, valued at $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 2.60% of the company’s stock.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the company. Capital World Investors lifted its stake in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the period. AQR Capital Management LLC raised its holdings in Illumina by 55.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock valued at $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Nordea Investment Management AB raised its holdings in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after acquiring an additional 911,843 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its stake in shares of Illumina by 140.1% during the 2nd quarter. Edmond DE Rothschild Holding S.A. now owns 1,428,692 shares of the life sciences company’s stock worth $136,312,000 after purchasing an additional 833,750 shares during the period. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Illumina by 1,558.0% during the second quarter. Thrivent Financial for Lutherans now owns 728,755 shares of the life sciences company’s stock worth $69,528,000 after purchasing an additional 684,802 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 beat on EPS and revenue — Illumina reported GAAP/non‑GAAP EPS of $1.35 (beat) and revenue of $1.16B (beat), with ex‑China growth stronger; management highlighted improving margins. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: FY‑2026 guidance mostly in line or better than Street — Illumina guided revenue to $4.5–$4.6B (above some estimates) and non‑GAAP EPS to $5.05–$5.20, signaling modest growth after recent year flatness. The guidance incorporates the SomaLogic acquisition and expected dilution. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
• Positive Sentiment: Underlying business trends cited as constructive — analysis points to clinical consumables growth, expansion into multiomics, and margin momentum that could support higher recurring revenue over time. ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum
• Neutral Sentiment: Call/transcript color: management reiterated strategy and provided details on growth drivers and the SomaLogic deal; read the call for guidance assumptions and segment commentary. Illumina Q4 2025 earnings call transcript Seeking Alpha transcript
• Negative Sentiment: Investors disappointed by FY‑2025 flat revenue and cautious tone — FY‑2025 revenue was essentially flat versus prior year, and some investors focused on slower organic growth and the near‑term dilution/costs from the SomaLogic acquisition, prompting selling pressure despite the EPS beat and guidance. Illumina shares tumble as flat revenue disappoints investors
• Negative Sentiment: Analyst/read‑through risk: even with some bullish commentary, markets may be repricing expectations for near‑term top‑line acceleration given mixed signals between margin upside and tepid full‑year growth. Analysts Are Bullish on Top Healthcare Stocks: Illumina (ILMN)

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.